Fig. 2.

Oestrogen-regulated genes following chemotherapy in early-stage breast cancer per menopausal status

Legend and captions. (a). Schematic trial design and tumour samples from the SOLTI-NEOERIBULIN phase II clinical trial(14). (b) Progesterone receptor (PGR) mRNA expression changes between baseline and after 4 cycles of eribulin monotherapy in 83 patients with residual tumours at surgery (i.e., 35 pre-menopausal and 53 post-menopausal). Each line represents a patient. Increases are represented in red and decreases in green. P- value (P) were determined using a two-tailed paired Student´s t-test. (c). Changes in gene expression after 4 cycles of eribulin in 83 patients included in the SOLTI-NEOERIBULIN trial per menopausal status. Heatmap shows high (red) / low (green) expression of mRNA. (d) Images and summary of progesterone receptor (PR) status by immunohistochemistry in residual tumours of 40 patients (13 pre-menopausal and 27 post- menopausal) with PR+/HER2-negative breast cancer treated with anthracycline/taxane- based neoadjuvant chemotherapy at the Hospital Clinic of Barcelona (Hematoxylin and eosin staining, original magnification x10). (e) Schematic trial design and tumour samples from 73 HER2+ early-stage breast patients treated with neoadjuvant anti-HER2-based multi-agent chemotherapy for 4-6 months, including HER2+/HR- (n=20) and HER2+/HR+/Luminal A or B (n=53) (f) Progesterone receptor (PGR) mRNA relative changes after 4-6 months of treatment in pre-menopausal and post-menopausal patients P-value (P) was determined using a two-tailed unpaired Mann-Whitney test. **: p<0.01.